NCT01710501View on ClinicalTrials.gov

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

November 25, 2013

Study Completion Date

January 29, 2014

Conditions
Chronic Hepatitis C (CHC)
Interventions
DRUG

Grazoprevir

Grazoprevir tablet, orally, once per day at assigned dose

BIOLOGICAL

pegylated interferon alfa-2b

1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection

DRUG

Ribavirin

Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight

DRUG

Placebo

Placebo to match grazoprevir tablets to maintain dose blinding

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01710501 - A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) | Biotech Hunter | Biotech Hunter